News Category
In vitro ADME studies are critical for early assessment of drug candidates, improving success rates and reducing costs in pharmaceutical development.
A new study reveals that the risk of sepsis, meningitis, or pneumonia from air pollution depends on individual bacterial strains, highlighting the nee...
Peptide Wholesale Supply now applies HPLC testing and batch traceability to bulk orders of BPC-157, Semaglutide, and Tirzepatide, enhancing analytical...
Patients with small cell lung cancer should ask about clinical trials at their first appointment, as emerging treatments offer new hope and improved q...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial could accelerate development of a new mpox vaccin...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNA gene therapy can restore full-length dystrophin and im...
Creative Biolabs has broadened its lipid-based delivery development capabilities to help researchers overcome stability, targeting, and controlled rel...
BioCorRx Inc. appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Advisory B...
Regentis Biomaterials reports progress in its Phase III GelrinC trial, a 400% manufacturing yield increase, and a reduced net loss for the first half ...
Quantum BioPharma has received FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class drug that aims to protect and rebuild the myelin ...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant that supports knee cartilage regeneration, with European approval and a...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® T-cell engager and othe...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, is moving toward a Phase 2 trial in multiple sclerosis following FDA clear...
Quantum BioPharma receives FDA clearance to launch a Phase 2 trial of Lucid-MS, the first drug designed to shield and rebuild myelin in multiple scler...
Quantum BioPharma has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class drug that aims to shield and potentially rebuild ...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, signaling the company's growing prominence ...
Onco-Innovations' CMO detailed the company's novel PNKP-targeting cancer drug ONC010, which uses synthetic lethality and nanoparticle delivery to pote...
Quantum BioPharma's FDA clearance to proceed with a Phase 2 trial of Lucid-MS marks a significant step for a first-in-class multiple sclerosis therapy...
An expert highlights the overlooked inadequacies in UTI diagnosis that lead to recurrent infections and broader health implications, underscoring the ...
Silo Pharma's participation in the IPAC-RS forum underscores the progress of its intranasal PTSD therapeutic, backed by robust stability data, signali...
Quantum BioPharma's Lucid-MS, a first-in-class candidate for multiple sclerosis, has cleared FDA Phase 2 trial approval, a significant step toward a p...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective drug candidate, has received FDA clearance to begin a Phase 2 trial, potentially tran...
GeoVax supports the new global mpox vaccine stockpile, highlighting its GEO-MVA candidate's readiness to contribute to sustainable and equitable vacci...
VERAXA Biotech's appointment of Raju Willener as CFO brings extensive financial leadership to support its capital strategy and oncology pipeline devel...
Scinai Immunotherapeutics strategically pivots its R&D to its NanoAb platform and CDMO business after terminating its PC111 license with PinCell, aimi...
Onco-Innovations Ltd. strengthens its clinical foundation for its lead candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor, through manufactu...
Quantum BioPharma's FDA clearance to test Lucid-MS in a Phase 2 trial marks a pivotal step toward the first therapy that may repair myelin in MS patie...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive brain cancer treatm...
Ocumetics Technology Corp. has initiated patient recruitment for the second group of its human clinical study, evaluating the safety and vision perfor...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial for MS marks a potential breakthrough in ...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the DRC, marking a critical step in developing an oral antivi...
Quantum BioPharma gains FDA clearance to begin a Phase 2 trial of Lucid-MS in multiple sclerosis, a potential first-in-class therapy targeting demyeli...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class remyelination agent, marks a pivotal step toward a new approach fo...
Quantum BioPharma's FDA clearance for its Phase 2 trial of Lucid-MS marks a significant step toward a targeted treatment for multiple sclerosis, poten...
Tonix Pharmaceuticals' promotion of Thomas Englese to Chief Commercial Officer underscores the company's strategic focus on expanding commercial opera...
A large study reveals that the timing of brain metastasis development significantly impacts survival in colorectal cancer patients, underscoring the n...
Onco-Innovations' ONC010, a PNKP inhibitor for cancer, has achieved high-purity API production and is progressing toward a First-in-Human study in Aus...
OS Therapies' participation in the Moody Capital conference underscores a pivotal period as it awaits key regulatory decisions and survival data for i...
A Swiss preclinical study suggests that administering immunotherapy prior to surgical removal of glioblastoma tumors significantly improves treatment ...
The FDA's failure to enforce laws against online sellers of the unapproved investigational drug retatrutide has enabled a dangerous black market that ...
New Mass General Brigham research links unintended thymus radiation during lung cancer treatment to worse outcomes, suggesting that protecting this im...
Tonix Pharmaceuticals' participation in a major healthcare conference underscores its strategic focus on advancing treatments for fibromyalgia and oth...
NurExone Biologic's participation in the Moody Capital Solutions 2026 conference underscores its strategic focus on advancing exosome-based therapies ...
CNS Pharmaceuticals' Chief Business Officer discusses the company's focus on building a pipeline in oncology and neurology through strategic in-licens...
Dr. Salman Fazal, a hematologist and stem cell transplant expert at UPMC Hillman Cancer Center, has been recognized as a Castle Connolly Top Doctor fo...
Quantum BioPharma's Lucid-MS drug candidate for progressive multiple sclerosis draws a 'Buy' rating from Rodman & Renshaw, highlighting its potential ...
NanoViricides is progressing its measles treatment NV-387 toward Phase II clinical trials, a critical step given the resurgence of measles cases and t...
TransCode Therapeutics announced that its lead candidate TTX-MC138 demonstrated significant survival benefits in a preclinical model of breast cancer ...
